- Home
- IMCR vs CUBI Comparison
IMCR vs CUBI Comparison
Compare IMCR & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- CUBI
- Stock Information
- Founded
- IMCR 2008
- CUBI 1994
- Country
- IMCR United Kingdom
- CUBI United States
- Employees
- IMCR N/A
- CUBI N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- CUBI Major Banks
- Sector
- IMCR Health Care
- CUBI Finance
- Exchange
- IMCR Nasdaq
- CUBI Nasdaq
- Market Cap
- IMCR 1.6B
- CUBI 1.7B
- IPO Year
- IMCR 2021
- CUBI 2012
- Fundamental
- Price
- IMCR $35.00
- CUBI $63.61
- Analyst Decision
- IMCR Buy
- CUBI Buy
- Analyst Count
- IMCR 10
- CUBI 9
- Target Price
- IMCR $58.13
- CUBI $67.38
- AVG Volume (30 Days)
- IMCR 383.2K
- CUBI 373.8K
- Earning Date
- IMCR 08-07-2025
- CUBI 07-24-2025
- Dividend Yield
- IMCR N/A
- CUBI N/A
- EPS Growth
- IMCR N/A
- CUBI N/A
- EPS
- IMCR N/A
- CUBI 3.98
- Revenue
- IMCR $333,581,000.00
- CUBI $591,500,000.00
- Revenue This Year
- IMCR $26.82
- CUBI $12.60
- Revenue Next Year
- IMCR $8.15
- CUBI $10.57
- P/E Ratio
- IMCR N/A
- CUBI $15.93
- Revenue Growth
- IMCR 25.75
- CUBI N/A
- 52 Week Low
- IMCR $23.15
- CUBI $40.75
- 52 Week High
- IMCR $41.54
- CUBI $68.49
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- CUBI 72.44
- Support Level
- IMCR $32.20
- CUBI $63.69
- Resistance Level
- IMCR $35.75
- CUBI $67.04
- Average True Range (ATR)
- IMCR 1.31
- CUBI 2.23
- MACD
- IMCR 0.28
- CUBI 0.47
- Stochastic Oscillator
- IMCR 84.94
- CUBI 77.54
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.